SCHEMBL5750409

SCHEMBL5750409

CCOC(=O)c1cc(F)cnc1Oc1cccc(SCC)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
NPSR1 Q6W5P4 4/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
POLB P06746 1/20 0.43
F10 P00742 2/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 4/20 0.40
HTT P42858 2/20 0.40
MAPK1 P28482 2/20 0.40
KMT2A Q03164 1/20 0.40
GRM7 Q14831 1/20 0.40
NMT2 O60551 2/20 0.39
NMT1 P30419 2/20 0.39
LMNA P02545 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5693370 0.90 NPSR1 (0.50) CYP1A2CYP2C9CYP2C19NPSR1L3MBTL1
SCHEMBL5749019 0.88 PTGER4 (0.44) CYP1A2CYP2C9CYP2C19NPSR1POLB
SCHEMBL5749360 0.80 L3MBTL1 (0.45) CYP1A2CYP2C9CYP2C19NPSR1L3MBTL1
SCHEMBL6063458 0.79 TSHR (0.44) CYP1A2CYP2C9CYP2C19NPSR1L3MBTL1
SCHEMBL8312606 0.79 PDE4B (0.51)
SCHEMBL6064161 0.78 CYP1A2 (0.60) CYP1A2CYP2C9CYP2C19NPSR1L3MBTL1
SCHEMBL8297693 0.77 PTGER4 (0.45) NPSR1ALDH1A1MAPTKMT2ALMNA
SCHEMBL5840163 0.77 CNR1 (0.44)
SCHEMBL5778510 0.77 P2RX7 (0.46) CYP1A2CYP2C9CYP2C19
SCHEMBL5839215 0.77 CNR1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7141586-B2 Nicotinamide derivatives useful as PDE4 inhibitors PFIZER INC. (US) 2006-11-28 US disclosed
EP-1651609-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS Pfizer Limited (GB) 2006-05-03 EP disclosed
US-20050032838-A1 Nicotinamide derivatives useful as PDE4 inhibitors PFIZER INC. 2005-02-10 US disclosed
WO-2005009966-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed
WO-2005009966-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032838-A1 Nicotinamide derivatives useful as PDE4 inhibitors CBR3, CBR1, PDE9A CYP1A2 555/4885CYP2C9 173/4885CYP2C19 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.